AURINIA PHARMACEUTICALS INC. v. SUN PHARMACEUTICAL INDUSTRIES, INC. et al

Filing 119

OPINION filed. Signed by Magistrate Judge Douglas E. Arpert on 8/2/2022. (jdg)

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 1 of 27 PageID: 4465

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
:
:
:
Plaintiff,
:
:
v.
:
:
SUN PHARMACEUTICAL INDUSTRIES, INC., :
et al.
:
:
Defendants.
:
:
AURINIA PHARMACEUTICALS INC.,

Civil Action No. 20-19805 (GC)(DEA)
OPINION

This matter comes before the Court on the following two motions: (1) a motion by
Plaintiff Aurinia Pharmaceuticals Inc. (“Aurinia” or “Plaintiff”) for leave to amend its
infringement contentions (ECF No. 47); and (2) a motion by Defendants Sun Pharmaceutical
Industries, Inc. and Sun Pharmaceutical Industries, Ltd. (collectively “Defendants” or “Sun”) for
leave to amend their counterclaims (ECF No. 91). The Court heard oral argument on June 14,
2022. For the reasons below, Plaintiff’s motion is granted in part and denied in part, and Sun’s
motion is granted.
I. Plaintiff’s Motion to Amend Its Infringement Contentions
This is a patent infringement action in which Plaintiff alleges that Defendants infringe
U.S. Patent Nos. 10,265,375 (the ’375 Patent) and 10,973,871 (the ’871 patent) (together, the
“Asserted Patents”) by Defendants’ commercial manufacture, use, offer to sell and sales of
Defendants’ CEQUA product, a calcineurin inhibitor immunosuppressant ophthalmic solution.
Pursuant to Local Patent Rule 3.7, Plaintiff moves to amend its infringement contentions.
Plaintiff states that the basis for the proposed amendments are documents that were produced by

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 2 of 27 PageID: 4466

Sun after the deadline for Plaintiff’s initial contentions concerning the nature and qualities of the
components of Sun’s allegedly infringing product.
A. Plaintiff’s Opening Arguments
According to Plaintiff, on July 1, 2021, Plaintiff served its first set of requests for
production of documents on Defendants, including requests for documents relating to
Defendants’ New Drug Application (“NDA”) and product formulation and specifications for the
accused product. Soon after, on July 12, 2021, Defendants demanded Plaintiff dismiss the action,
alleging that CEQUA does not infringe the Asserted Patents based on third-party testing of the
surfactants used in CEQUA. Defendants contended that the testing allegedly showed that the two
surfactants do not have an absolute difference of greater than about 3 as required by the asserted
claims. 1 Plaintiff disagreed based on publicly available information and requested from Sun
complete documentation around the third-party testing.
In accordance with the Scheduling Order, Plaintiff served its disclosure of asserted claims
and infringement contentions on July 27, 2021 and amended those contentions a few days later.
According to Plaintiff, at that time, Sun had not produced any non-public technical documents
showing “the nature and qualities of the components of their infringing CEQUA product,
including without limitation, non-publicly available information contained in their NDA and
product specifications or documents relating to the secret third party testing.” ECF No. 47-1 at 6.

The Asserted Patents independent claim limitations require “a pharmaceutical composition comprising a
calcineurin inhibitor or mTOR inhibitor, a first surfactant with an HLB index greater than about 10, and a second
surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of
the first surfactant and the HLB index of the second surfactant is greater than about 3, wherein the composition is
in the form of mixed micelles having the first and second surfactants; and wherein the composition contains less
than 2% by weight ethanol.” ECF Nos. 1, 20. The claim limitations requiring “a first surfactant with an HLB index
greater than about 10, and a second surfactant with an HLB index of greater than about 13, wherein an absolute
difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than
about 3” are also required by the remaining asserted dependent claims of the Asserted Patents. Id.

1

2

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 3 of 27 PageID: 4467

Plaintiff states that it continued to seek production of the documents relating to the thirdparty testing through further correspondences and meet and confers. Defendants served their
initial Non-Infringement Contentions on September 15, 2021, but, according to Plaintiff, did not
provide any underlying documentation to support its assertion that the HLB limitations were
absent. After further communications between the parties, on October 15, 2021, Defendants
produced certain documentation related to the third-party testing. Defendants continued to
supplement their production through December 7, 2021. According to Plaintiff, the December 7th
supplemental production contained key information regarding Defendants’ representations to the
FDA regarding the nature and qualities of the surfactants used in CEQUA relevant to its
infringement contentions.
On December 23, 2021, Plaintiff served Second Amended Infringement contentions, and
on January 3, 2022, Defendants stated they would not consent to the amendment. This motion
followed.
In its moving brief, Plaintiff argues that (1) good cause exists to permit amendment; and
(2) the amendment does not prejudice Defendants. As to good cause, Plaintiff asserts it acted
diligently and promptly in supplementing its infringement contentions as new, nonpublic
information became available to it. Plaintiff claims it acted diligently in attempting to obtain the
non-public information and, once it acquired the information, it acted promptly in seeking to
amend its contentions.
As to prejudice, Plaintiff contends that Defendants cannot be surprised by the proposed
amendment given that Plaintiff is citing Defendants’ own information, which Defendants have
had knowledge of this information in its possession and control since the outset of this case.
Further, Plaintiff claims that its proposed amendment will not result in any additional burden or

3

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 4 of 27 PageID: 4468

costs to Defendants because it does not add new products, patents or even claims to the case.
Last, Plaintiff asserts that the proposed amendment will not cause any delay in the case.
B. Defendants’ Responsive Arguments
Defendants do not oppose Plaintiff amending its contentions “to only add citations to
non-public documents produced by Sun after Aurinia’s initial contentions deadline.” ECF No. 53
at 2. However, Defendants oppose the motion in all other respects and argue that the
amendments Plaintiff seeks “dramatically change and redo its infringement contentions.” Id. at 3.
According to Sun, shortly after receiving Plaintiff’s initial infringement contentions on
July 27, 2021, Defendants informed Plaintiff that its contentions were deficient. Specifically,
Defendants state that they pointed out “Aurinia’s failure to comply with the Local Patent Rules
by (i) providing only boilerplate allegations of infringement under [the Doctrine of Equivalents]
…; (ii) failing to identify its own product that allegedly practices the alleged invention of the
Asserted Patents; and (iii) failing to separately identify by production number the documents for
each category of Aurinia’s contentions, as required by L. Pat. R. 3.2(g).” Id. Three days later,
Plaintiff served its first set of Amended Contentions, but, according to Defendant, other than
identifying the documents required under Local Patent Rule 3.2(g), Plaintiff did not correct any
of the deficiencies identified by Sun.
Defendants allege that they continued to advise Plaintiff that its contentions were
deficient under the Local Patent Rules. According to Sun, Plaintiff maintained that its
contentions satisfied the Local Patent Rules and never sought to amend to address the alleged
deficiencies identified by Defendants.
Sun disputes Plaintiff’s assertion that the proposed amendments are based on “new
information recently identified by Aurinia during discovery.” Sun contends that Plaintiff’s

4

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 5 of 27 PageID: 4469

proposed amendments include much more. For example, Defendants point to, “13 pages of new
practicing product allegations and tens of new [Doctrine of Equivalents] arguments” and argue
that Plaintiff provides no explanation as to how any of the “new information recently identified
by Aurinia during discovery” relates to these amendments. ECF No. 53 at 5-6. Defendants point
to the following specific amendments that they contend are improper:
First, Defendants point to Plaintiff’s disclosure requirement regarding its own product
under Local Patent Rule 3.1(g). 2 Sun notes that in Plaintiff’s Initial Contentions and First
Amended Contentions Plaintiff’s entire disclosure pursuant to Local Patent Rule 3.1(g) regarding
its own product was a single sentence: “Aurinia has had an ophthalmic pharmaceutical product in
commercial development since at least 2015.” Plaintiff cited no documents (in its Initial
Contentions), did no claim chart mapping, and provided no product name. Defendants allege that
defense counsel repeatedly wrote to Plaintiff complaining of the deficiencies in Plaintiff’s 3.1(g)
contentions, advising that Plaintiff’s failure to show how its own product mapped to the asserted
claims was prejudicing Sun’s ability to prepare its case. Sun states that now, in its proposed
Second Amended Contentions, Plaintiff for the first time provides 13 pages of new claim-byclaim contentions for its allegedly practicing product and cites documents allegedly in support
thereof. Plaintiff, however, has provided no explanation as to why it waited so long to provide
this information. Because the information about Plaintiff’s alleged practicing product has been
within Plaintiff’s possession, custody, and control, Sun argues that Plaintiff has not shown good
cause for this amendment. Further, Defendants contend they would be prejudiced, as they may

Local Patent Rule 3.1(g) provides: “If a party asserting patent infringement wishes to preserve the right to rely,
for any purpose, on the assertion that its own apparatus, product, device, process, method, act, or other
instrumentality practices the claimed invention, the party shall identify, separately for each asserted claim, each
such apparatus, product, device, process, method, act, or other instrumentality that incorporates or reflects that
particular claim”.

2

5

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 6 of 27 PageID: 4470

have utilized different discovery requests or interrogatories, or developed new and/or different
defenses, had they known this new information regarding the purportedly practicing product.
Second, Defendants contend that the amendments regarding Plaintiff’s new Doctrine of
Equivalents (“DOE”) arguments should not be permitted. Sun argues that Plaintiff fails to
specifically address these amendments in its briefing and does not articulate any good cause for
this amendment. According to Sun, Plaintiff’s Initial and First Amended Contentions included
only insufficient, boilerplate DOE allegations that do not meet the requirements of this District’s
Local Patent Rules. Specifically, for each and every limitation, Plaintiff simply asserted that
Defendants’ mode of infringement was “Direct or Under the Doctrine of Equivalents”. Sun
notes that despite Sun’s repeated complaints about this deficiency, Plaintiff waited until now to
seek to amend its DOE theories. Defendants contend that the proposed DOE contentions are
untimely, lack good cause, and prejudice Defendants. In particular, Sun states that the new DOE
arguments do not provide a citation to any Sun document (i.e., the purported justification for the
proposed amendments), and do not provide a reason that these assertions could not have been
made in the earlier-served contentions. As to prejudice (an issue which Defendants argue is not
necessary to reach due to the lack of good cause), Sun claims to have been disadvantaged in the
claim construction process, specifically in understanding how Plaintiff thought Sun’s CEQUA
product read on the claims.
Third, Sun alleges that Plaintiff supplemented its claim charts with citations to documents
other than the new Sun documents. For example, Plaintiff also adds citations to pages in
documents that it clearly was aware of because those same documents were cited in prior
versions of its contentions. Defendants contend that it is too late for Plaintiff to now supplement

6

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 7 of 27 PageID: 4471

its contentions with citations it was aware of when it served its Initial and First Amended
Contentions.
Finally, Defendants point out that Plaintiff’s proposed Second Amended Contentions
includes an entirely new section, “Response to Defendants’ Noninfringement Contentions.”
Defendants maintain that this amendment is outside what the Local Patent Rules permit, and that
Plaintiff has not articulated any good cause showing that this amendment is proper. Sun
contends, contrary to Plaintiff’s assertions, that it never kept any part of its testing to show
noninfringement a “secret”, and it provided Aurinia with a report reflecting its testing of the
surfactants used in Sun’s accused CEQUA product prior to Plaintiff’s initial contentions being
served.
C. Plaintiff’s Reply
In response to Sun’s assertions that the proposed Second Amended Contentions contain
amendments not based on the new discovery produced by Sun, Plaintiff states that its proposed
amendments merely “clarify and provide additional detail on Aurinia’s existing infringement
theories based primarily on the withheld information.” ECF No. 55 at 3-4. First addressing Sun’s
assertions regarding Plaintiff’s Rule 3.1(g) disclosures, Plaintiff takes issue with Defendants’
claim that it provided only a single sentence in both sets of contentions. Plaintiff notes that in its
First Amended Contentions, in addition to the single sentence pointed to by Defendants, Plaintiff
also provided citations to a number of documents. Plaintiff further argues that its proposed
amendment clarifies and provides greater detail on the contentions already asserted about its
practicing product. It contends that the proposed amendment does not assert any new practicing
products and does not add additional asserted claims, but rather “reduces the number of asserted
claims and provides clarity to Aurinia’s earlier contentions to avoid unnecessary disputes during

7

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 8 of 27 PageID: 4472

discovery.” Id. at 6. Plaintiff claims that contrary to the assertions by Defendants, there is no
prejudice to Defendants because Plaintiff is not introducing any “new” information into the case.
Turning next to Defendants’ arguments regarding the DOE, Plaintiff contends that its
earlier disclosures were not “insufficient” as alleged and, further, that its proposed amendment
does not present “new” DOE theories late in the case. Plaintiff claims to be seeking “to amend its
contentions to clarify and provide greater detail.” Id. at 10. Plaintiff asserts it “acted diligently
and timely in refining its infringement contentions as new, nonpublic information was produced
by Defendants in October and December, e.g., the source and precise composition of the
surfactants used in Defendants’ infringing product.” Id. For example, Plaintiff points to its DOE
assertions tied to the literal infringement assertions for claim 1 of the ’375 Patent, which cite to
ten documents produced by Defendants after Aurinia’s initial infringement contentions were due,
six of which were produced on December 7, 2021. Plaintiff further argues that Defendants can
point to no real prejudice, as Defendants identify no actual terms needing construction and fail to
identify any such issue in their subsequently filed Opening Claim Construction Brief.
Addressing Sun’s assertion that Plaintiff’s responses to Defendants’ noninfringement
contentions should not be permitted, Plaintiff contends this position is “without merit” because:
(1) any additional page citations are not prejudicial to Sun and were in response to Defendants’
assertion that its product lacked certain claim elements; and (2) while Sun produced a 2-page
report regarding alleged testing, Sun withheld the information underlying the testing for many
months.
Last, Plaintiff reasserts that, overall, its proposed amendments would not prejudice
Defendants in any way.

8

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 9 of 27 PageID: 4473

D. Sun’s Sur-Reply
Sun requested leave to file a sur-reply brief, and the Court has reviewed and considered
the sur-reply brief. Sun contends that Plaintiff’s Reply fails to address the appropriate legal
standard regarding amendment of contentions, noting, in particular, that
[d]iligence of the moving party is … the dominant consideration in determining
whether good cause exists under Rule 3.7. … Moreover, the Court need not
consider whether the non-party would suffer prejudice unless it has first found the
moving party was diligent in discovering that an amendment was appropriate and
then promptly moved to amend its contentions.
Razor USA LLC v. DGL Group, Ltd., No. 19-12939, 2022 WL 44627, at *6 (D.N.J. Jan. 5, 2022)
(internal citations omitted). Sun points out that Plaintiff’s arguments focus primarily on an
alleged lack of prejudice to Sun.
As to Plaintiff’s proposed amendments regarding its own practicing product, Sun disputes
Plaintiff’s claims that its allegations regarding its practicing product are “not new”. Sun
reiterates that Aurinia’s initial contentions contained a single sentence disclosure regarding its
practicing product and citation to five documents, and Aurinia has made no attempt to tie the
alleged reason for the proposed amendment directly to the 13-page amendment of this section.
Further, Sun contends that Aurinia’s allegations that its proposed amendments reduce the
number of asserted claims is factually wrong, and the proposed amendments alter only the claims
that Aurinia alleges are practiced by its own product. Sun states that Plaintiff’s proposed
amendments now asserts that its product practices two claims—claims 12 and 27 of the ʼ375
patent—that were never previously asserted against Sun.
Sun maintains that Aurinia provides no rationale for why it should be allowed to now add
new claim mapping and new documents to support its allegedly practicing product claims.

9

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 10 of 27 PageID: 4474

Because Aurinia cannot establish it was diligent in seeking to add these, Sun contends it should
be prevented from amending its contentions pursuant to Local Patent Rule 3.1(g).
Turning to Plaintiff’s proposed DOE amendments, Sun takes issue with Plaintiff’s claims
that its DOE theories are not new, but rather are meant to “clarify and provide greater detail.”
Sun notes that parties are not permitted to assert a general DOE theory and then proffer a more
specific theory “when it becomes convenient”. Howmedica Osteonics Corp. v. Depuy
Orthopaedics, Inc., No. 11-6498, 2014 WL 6675923, at *5 (D.N.J. Oct. 19, 2014) (“A patentee
cannot be permitted to assert a general DOE theory of infringement and then proffer a more
specific DOE theory whenever it becomes convenient for it to do so.”). Further, Sun contends
that Plaintiff falsely alleges that its “DOE assertions tied to Aurinia’s literal infringement
assertions” cite to new documents, and that a review of the redline document proves that none of
Aurinia’s new DOE allegations cite to any new documents, nor do they cite to the new Sun
documents that provide the alleged good cause for Aurinia’s amendments. Sun states that it has
no objection to Aurinia’s additional citations to non-public documents produced after Aurinia’s
contentions were due but maintains that these documents have no discernible relationship to
Aurinia’s DOE allegations and cannot provide good cause to amend Aurinia’s DOE contentions.
Overall, Sun reasserts that the later-produced documents do not provide Aurinia good
cause to for the extensive amendments sought, arguing that the good cause analysis must tie new
documents directly to the proposed amendments, and that Plaintiff has failed to make this
showing.
E. Analysis
Local Patent Rule 3.7 governs amendments of infringement contentions. Pursuant to
Local Patent Rule 3.7, “Amendment of any contentions ... may be made only by order of the

10

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 11 of 27 PageID: 4475

Court upon a timely application and showing of good cause.” Local Patent Rule 3.7 sets forth a
“[n]on-exhaustive” list of “examples of circumstances that may, absent undue prejudice to the
adverse party, support a finding of good cause.” As relevant to the present case, these
circumstances include: “… (c) recent discovery of nonpublic information about the Accused
Instrumentality which was not discovered, despite diligent efforts, before the service of the
Infringement Contention; …” L.Pat.R. 3.7. As explicitly noted in the Rule, this list is nonexhaustive and other circumstances may arise justifying the amendment of contentions.
The Local Patent Rules “are designed to require parties to crystallize their theories of the
case early in the litigation and to adhere to those theories once they have been disclosed.” Razor
USA LLC v. DGL Grp., Ltd., No. 19-12939, 2022 WL 44627, at *3 (D.N.J. Jan. 5, 2022). The
Rules “seek to balance the right to develop new information in discovery with the need for
certainty as to legal theories.” Nautilus Neurosciences, Inc. v. Wockhardt USA LLC, No. 111997, 2013 WL 7901901, at *2 (D.N.J. Jan. 23, 2013). Courts have noted that, unlike the liberal
standard for amending pleadings under Federal Rule of Civil Procedure 15(a), Patent Rule 3.7
implements a “conservative” approach to amending contentions, “designed to prevent the
‘shifting sands’ approach to claim construction.” King Pharm., Inc. v. Sandoz Inc., No. 08-5974,
2010 WL 2015258 at *4 (D.N.J. May 20, 2010). Satisfying the requirements of Rule 3.7 “is not a
simple undertaking and requires the movant to overcome a substantial preference against
granting the amendment.” Nautilus Neurosciences, 2013 WL 7901901, at *2. Even so, the rule
“is not a straitjacket into which litigants are locked from the moment their contentions are
served,” but rather allows “a modest degree of flexibility, at least near the outset.” Merck Sharp
& Dohme Corp. v. Sandoz, Inc., No. 12-3289, 2014 WL 1494592, at *8 (D.N.J. Apr. 16, 2014).

11

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 12 of 27 PageID: 4476

Under Patent Rule 3.7, the Court may grant leave to amend infringement contentions
upon a showing that (1) the application is timely; (2) there is good cause for the amendment; and
(3) the adverse party will not suffer undue prejudice if leave to amend is granted. Razor USA,
2022 WL 44627, at *4 (citing Celgene Corp. v. Natco Pharma Ltd., No. 10-5197, 2015 WL
4138982, at *4 (D.N.J. July 9, 2015)). The burden is on the moving party to demonstrate these
criteria are met. Jazz Pharms., Inc. v. Roxane Labs., Inc., No. 10-6108, 2013 WL 785067, at *2-3
(D.N.J. Feb. 28, 2013).
It is Plaintiff’s burden to establish the three necessary elements to grant this motion. First
is whether the application is timely. To the extent that Plaintiff’s proposed Second Amended
Contentions include the addition of citations to non-public documents produced by Sun after
Plaintiff’s initial contention deadline, those proposed amendments are timely. However, the vast
majority of the proposed amendments are not based upon these new documents. For example,
with respect to its own practicing product (for which Plaintiff itself presumably has possessed the
relevant information), Plaintiff proposes 13-pages of amendments that it claims “clarifies and
provides greater detail on the contentions already asserted about its practicing product.” Plaintiff
also claims the amendments “clarify” its DOE assertions and, overall, “clarify” its infringement
contentions. But absent a connection to the new information purportedly relied upon, such a
“clarification” is untimely. The Court agrees with Defendants that Plaintiff has not made that
connection.
Turning to the second factor, Plaintiff also must show that good cause exists for the
amendment. Here again, Plaintiff points to the new information produced by Defendants in
discovery as purportedly establishing good cause. However, as noted, Plaintiff has not shown
there is a link between the amendments and the non-public documents produced by Defendants

12

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 13 of 27 PageID: 4477

after Plaintiff served its initial contentions. As such, good cause has not been established. The
amendments are extensive, and Plaintiff has failed to draw a clear connection to most of the
proposed amendments and the new information received.
Overall, Plaintiff’s arguments focus heavily on the third prong of the analysis, i.e., its
assertion that there will be no prejudice to Sun by the proposed amendments. Sun, on the other
hand, argues it would suffer prejudice if the amendments are permitted. However, the Court need
not resolve that question. “While lack of prejudice to the non-moving party must also be
established to obtain leave to amend under Rule 3.7, this requirement need not be evaluated
unless the moving party has shown it was diligent in discovering that an amendment was
appropriate and promptly moved to amend its contentions.” Razor USA LLC v. DGL Grp., Ltd.,
No. 19-12939, 2022 WL 714736, at *6 (D.N.J. Mar. 10, 2022). Plaintiff has failed to establish
the first two factors of the analysis, therefore the Court does not consider the third factor.
In sum, the Court finds that, with limited exception, Plaintiff’s proposed Second
Amended Contentions are neither timely nor supported by good cause. Plaintiff’s motion,
therefore, is denied in all aspects but one. The Court will permit the proposed amendment only to
the extent citations were added to documents produced by Sun after Aurinia’s initial contentions
deadline. The motion for leave to amend is denied in all other respects.
II. Sun’s Motion to Amend Its Counterclaims to Add Inequitable Conduct
Sun seeks to amend its counterclaims to allege that the Asserted Patents are
unenforceable under the doctrine of inequitable conduct. Specifically, Sun’s proposed
counterclaim alleges that Aurinia and its attorneys committed inequitable conduct by failing to
include Dr. Kishore Cholkar as an inventor on the ’375 and ’871 Patents.

13

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 14 of 27 PageID: 4478

Dr. Cholkar was a Ph.D. student at University of Missouri-Kansas City (“UMKC”)
working with Dr. Ashim K. Mitra, a named inventor listed on the Asserted Patents, beginning in
approximately April 2008. According to Sun, Dr. Cholkar worked to develop stable ophthalmic
compositions with calcineurin inhibitors or mTOR inhibitors for treating ocular diseases and
conditions, including with voclosporin. Sun asserts that as a result of Dr. Cholkar’s extensive
studies, conception, and experimentation, each independent claim of the Asserted Patents
contains the limitation, “wherein the composition contains less than 2% by weight ethanol.”
According to Defendants, in 2018, Dr. Cholkar was in communication with Aurinia and
worked with the attorneys prosecuting U.S. Application No. 14/627,063 (the “‘063 Application”)
that issued as the ’375 Patent. Sun states that Dr. Cholkar worked with Aurinia and its attorneys
to draft a declaration in support of the patentability of the ’063 Application. In particular, Mr.
Michael Martin, who is the current Chief Business Officer of Aurinia, approached Dr. Cholkar to
discuss the declaration. Sun alleges that Mr. Martin met in-person with Dr. Cholkar and during
the meeting stated to Dr. Cholkar that he knew Dr. Cholkar should have been named as a
coinventor on the ‘063 Application. On May 11, 2018, Dr. Cholkar submitted the signed
declaration in support of the invention disclosed in the ‘063 Application under 37 C.F.R. § 1.132.
However, according to Sun, despite Mr. Martin’s acknowledgement of Dr. Cholkar’s
contribution to the claimed subject matter of the ‘063 Application, Dr. Cholkar was not named as
a co-inventor.
On March 23, 2022, Sun served a subpoena to UMKC seeking documents related to the
research and development work for the subject matter of the Asserted Patents. Sun received
responsive documents from UMKC and produced them to Aurinia on April 13, 2022. Sun claims
the documents that UMKC provided showed that Dr. Cholkar was involved with key studies

14

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 15 of 27 PageID: 4479

contributing to the alleged invention of the Asserted Patents. According to Sun, once Defendants
fully learned the facts and circumstances detailed in its proposed Counterclaims, Sun notified
Aurinia of its intention to amend its pleading. Plaintiff opposes the amendment.
A. Legal Standard
Pursuant to Federal Rule of Civil Procedure 15, leave to amend the pleadings is to be
granted freely “when justice so requires.” The Federal Rules of Civil Procedure allow for
amendments to be granted liberally in light of the “principle that the purpose of pleading is to
facilitate a proper decision on the merits.” Foman v. Davis, 371 U.S. 178, 182 (1962) (citation
and internal quotation marks omitted). Nevertheless, the Court may deny a motion to amend
where there is “undue delay, bad faith or dilatory motive on the part of the movant, repeated
failure to cure deficiencies by amendments previously allowed, undue prejudice to the opposing
party by virtue of allowance of the amendment, [or] futility of the amendment.” Id. However,
where there is an absence of these factors, a motion for leave to amend a pleading should be
liberally granted. Long v. Wilson, 393 F.3d 390, 400 (3d Cir. 2004).
Plaintiff contends that leave to amend should be denied on the basis of futility, undue
delay, and prejudice. The Court addresses each below.
B. Futility
The futility analysis on a motion to amend is essentially the same as a Rule 12(b)(6)
motion. See In re NAHC, Inc. Sec. Litig., 306 F.3d 1314, 1332 (3d Cir. 2002). The proposed
amended claim “must contain sufficient factual matter, accepted as true, to ‘state a claim to relief
that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Bell Atl. Corp.
v. Twombly, 550 U.S. 544, 570 (2007)). “A claim has facial plausibility when the plaintiff pleads
factual content that allows the court to draw the reasonable inference that the defendant is liable

15

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 16 of 27 PageID: 4480

for the misconduct alleged.” Id. “[G]iven the liberal standard for the amendment of pleadings,
‘courts place a heavy burden on opponents who wish to declare a proposed amendment futile.’”
Brainbuilders, LLC v. Optum, Inc., No. 18-638, 2019 WL 2315389, at *5 (D.N.J. May 31, 2019).
Therefore, “[i]f a proposed amendment is not clearly futile, then denial of leave to amend is
improper.” Id.
“Inequitable conduct is an equitable defense to patent infringement that, if proved, bars
enforcement of a patent.” Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276, 1285
(Fed. Cir. 2011). A claim for inequitable conduct requires that (1) “the patentee acted with the
specific intent to deceive the [Patent and Trademark Office (“PTO”)],” and (2) the material
withheld from the PTO satisfies “but-for materiality,” that is, the PTO would not have allowed a
claim had it been aware of the undisclosed material. Therasense, 649 F.3d at 1290-91. A party
claiming inequitable conduct ordinarily must show that the patentee “withheld or misrepresented
information that, in the absence of the withholding or misrepresentation, would have prevented a
patent claim from issuing.” Ohio Willow Wood Co. v. Alsp S., LLC, 735 F.3d 1333, 1345 (Fed.
Cir. 2013).
A counterclaim or affirmative defense of inequitable conduct sounds in fraud and
therefore is subject to the heightened pleading standard of Fed. R. Civ. P. 9(b). “‘Whether
inequitable conduct has been pleaded with particularity under Rule 9(b) is a question governed
by Federal Circuit law.’” Sanders v. The Mosaic Co., 418 F. App'x 914, 918 (Fed. Cir. 2011)
(quoting Exergen Corp. v. Wal-Mart Stores, Inc., 575 F.3d 1312, 1318 (Fed. Cir. 2009)). “To
plead inequitable conduct, ‘the pleading must identify the specific who, what, when, where, and
how of the material misrepresentation or omission committed before the PTO.’” Id. (quoting
Exergen).

16

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 17 of 27 PageID: 4481

Plaintiff first alleges that the proposed amendment fails to meet the materiality standard
because Sun fails to plead plausible facts that Dr. Cholkar was an inventor. Plaintiff points to
Sun’s assertions that Dr. Cholkar allegedly (1) contributed to conception of the patent claim
limitation “wherein the composition contains less than 2% by weight ethanol”; (2) “examined the
method of mixing the formulation to 95% ethanol to form an ethanolic solution and then
evaporating the ethanolic solution to form a near-solid matter[, resulting] in near-solid matter
that was essentially free of ethanol (about <2% ethanol)”; and (3) joined the laboratory of Dr.
Mitra at UMKC beginning in April 2008 where his alleged work and contributions subsequently
were allegedly performed. According to Plaintiff, however, the alleged conception (1) of being
essentially free of ethanol (less than 2% ethanol) and (2) of mixing 95% ethanol to form an
ethanolic solution and then evaporating the ethanolic solution to form a near-solid matter, was
disclosed in Aurinia’s provisional patent application (Aurinia’s Provisional Application No.
60/997,796, dated October 8, 2007) six months before Dr. Cholkar joined UMKC.
Plaintiff also contends that the first example in the October 2007 provisional application
specifically describes protocols for experiments of the same subject matter six months before Dr.
Cholkar even joined UMKC to start work. As such, Plaintiff claims that Defendants’ allegation
that Dr. Cholkar contributed to the conception of less than 2% ethanol is not plausible under the
Rule 12(b)(6) standards.
Plaintiff maintains that other allegations confirm the lack of plausibility of the inequitable
conduct defense. First, they point to Defendants’ citations to nine documents produced by
UMKC to support the allegation that Dr. Cholkar contributed to the claim limitation, even
though, according to Plaintiff, 8 out of these 9 documents are stand-alone documents that do not

17

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 18 of 27 PageID: 4482

mention Dr. Cholkar’s name. And the one that does mention his name allegedly makes no
specific attribution to Dr. Cholkar as conceiving of a less than 2% ethanol subject matter.
Second, Plaintiff notes that Dr. Cholkar did not represent himself to the Patent Office to
be an inventor even though he knew and understood fully Aurinia’s patent application.
Defendants’ proposed amended pleading references Dr. Cholkar’s May 11, 2018 expert
declaration filed by Aurinia in the Patent Office in support of the patentability of the ’063
Application. This declaration avers that (1) he was fully aware of the contents of Aurinia’s patent
application disclosing the same less than 2% subject matter, (2) that he was not listed as an
inventor on the application and (3) had no financial interest in the outcome of the ’063
Application.
Third, Plaintiff contends that even if Dr. Cholkar should have been named as an inventor,
such failure does not support a claim of inequitable conduct. Plaintiff points out that some courts
have held that improper inventorship does not meet the “but-for” materiality requirement under
Therasense. See, e.g., Auxilium Pharms., Inc. v. Watson Lab’ys, Inc., No. CIV.A. 12-3084, 2014
WL 9859224, at *35 (D.N.J. Dec. 16, 2014) (“[I]ncorrect inventorship evidence is not but-for
material under Therasense.”).
Plaintiff further argues that Defendants’ Proposed Amendment fails to meet the Exergen
standard of specifically alleging the who, what, when, where, and how of the material
misrepresentation or omission committed before the PTO. As to the “who,” Plaintiff assert that it
is insufficient for Defendants to allege that “Aurinia and its attorneys” had a duty of candor and
good faith in dealing with the USPTO. While Plaintiff concedes that Defendants’ Proposed
Amendment does mention Mr. Michael Martin’s name, Plaintiff claims that Defendants plead no
facts beyond the conclusory allegation that Mr. Martin allegedly stated that he knew Dr. Cholkar

18

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 19 of 27 PageID: 4483

should have been named as a co-inventor on the ’063 Application. Plaintiff maintains that this
allegation is belied by Dr. Cholkar’s averment of non-inventorship to the Patent Office and is not
plausible.
Further, Defendants allege Mr. Martin met with Dr. Cholkar for purposes of discussing
an expert declaration when he made this alleged statement. Plaintiffs point out that with this
supposed knowledge, Dr. Cholkar then avers he is properly not listed as an inventor even though
Dr. Cholkar avers he fully understood the subject matter of the Aurinia patent application.
Plaintiff characterizes Defendants’ allegations as asking the Court to leap to an inference of
specific intent to deceive the PTO based on an inventorship allegation by a non-attorney without
pleading any facts about (1) whether Mr. Martin knew the legal requirements for an inventor
under the patent law, (2) whether he was using the term “inventor” colloquially or in accordance
with the patent law, and (3) whether he intentionally caused his attorneys not to list Dr. Cholkar
on the list of inventors when filing and maintaining the ’063 Application. Thus, Plaintiff
contends that Defendants have failed to plead facts “from which a court may reasonably infer
that a party acted with the requisite state of mind.” Exergen, 575 F.3d at 1327.
Finally, Plaintiff argues that Sun appears to be taking the position that because
inventorship may be material to the PTO examination, it is sufficient to support an inference of
intent to deceive. Plaintiff contends that under Therasense, courts “may not infer intent solely
from materiality” and that “[i]ntent and materiality are separate requirements.” Therasense, 649
F.3d at 1290.
In response, Sun asserts that Plaintiff’s arguments, although couched in terms of
plausibility, are in reality factual disputes. For example, Sun claims that the provisional patent
application Plaintiff points to is not dispositive of the inventorship issue, but rather highlights the

19

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 20 of 27 PageID: 4484

factual disputes that exist between the parties related to the allegations in Sun’s proposed
amended pleading. Although Plaintiff asserts that the provisional application shows that Dr.
Cholkar could not have invented the alcohol limitations recited in the ultimately issued patent
claims, Sun states that the application specifically does not claim any subject matter related to
the use of alcohol. Defendants, in fact, contend that differences between the disclosure in the
provisional application and the language that ultimately appears in the issued patent claims is a
result of Dr. Cholkar conducting numerous studies. As such, Sun asserts Dr. Cholkar conceived
of part of the claimed invention.
Sun further argues that Plaintiff’s additional points also relate to factual disputes between
the parties and do not touch on the plausibility of the proposed counterclaims. Aurinia attaches a
number of documents to its Opposition that Sun received from UMKC in response to Sun’s
document subpoena. These documents allegedly reflect studies and results from Dr. Cholkar’s
work on the project that led to the claimed invention. While Aurinia points out that Dr. Cholkar’s
name is not recorded on these documents, Sun argues this is inapposite. Sun states that it is not
uncommon that an investigator’s name is not included on raw data documenting work product,
and further, that Plaintiff presents no evidence that these documents do not demonstrate Dr.
Cholkar’s work.
Sun also points to the declaration of Dr. Cholkar’s relied on by Plaintiff that was
submitted during the prosecution of the ’375 Patent in support of its patentability. Plaintiff
argues this declaration shows that Dr. Cholkar did not claim to be a coinventor, but Sun contends
that Aurinia mischaracterizes this declaration as a disavowal of inventorship by Dr. Cholkar. Sun
notes that in the declaration Dr. Cholkar merely recognizes that he “is not a listed inventor” on
the pending patent application and goes on to provide information in support of patentability.

20

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 21 of 27 PageID: 4485

Sun argues that its proposed amended pleading properly alleges the who, what, when,
where, and how of the material misrepresentation or omission committed by Aurinia before the
U.S. Patent and Trademark Office. As to who, Sun’s proposed amended pleading goes beyond
merely alleging wrongdoing by an organization and its attorneys, and specifically alleges
wrongdoing by Aurinia’s current Chief Business Officer, Mr. Michael Martin. To the extent that
Aurinia asserts that Mr. Martin may not have fully understood the legal requirements of
inventorship and may have been using the term inventor “colloquially,” Sun maintains that this
merely highlights a potential fact dispute between the parties.
Sun points to a district court decision outside of this district that, contrary to the district
court decision cited by Plaintiff, found that inventorship is a critical requirement for obtaining a
patent, and can be considered “but for” material. Imprenta Servs., Inc. v. Karll, No. 22-6177,
2021 WL 4555333, at *3 (C.D. Cal. July 13, 2021) (“[A] full and accurate disclosure” of correct
inventorship “is a critical requirement for obtaining a patent . . . [i]nventorship, then, is but-for
material.”). Sun also contends that purposefully omitting a coinventor during prosecution can
qualify as egregious misconduct, since incorrect inventorship directly affects the validity of a
patent. See Therasense, Inc. v. Becton, Dickinson and Co., 649 F.3d 1276, 1291 (Fed. Cir. 2011)
(“When the patentee has engaged in affirmative acts of egregious misconduct . . . the misconduct
is material.”).
According to Sun, Aurinia also incorrectly claims that Sun infers deceptive intent only
from its allegations of materiality. Defendants claim such an argument ignores the other
allegations in Sun’s amended counterclaims. Sun contends that, when the factual allegations in
its proposed amended pleading are taken as a whole, a reasonable fact finder could infer
deceptive intent to support a claim of inequitable conduct from the facts alleged by Sun.

21

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 22 of 27 PageID: 4486

The futility analysis requires to the Court to evaluate whether a claim is clearly futile on
its face. While Plaintiff clearly disagrees with the assertions in Sun’s proposed inequitable
conduct claim and raises a number of merits-based challenges to the facts asserted, such
disagreement does not render the claim implausible for the purposes of a Rule 15 analysis. The
Court agrees with Sun that much of Plaintiff’s futility argument highlights factual and legal
disputes on the issues rather than plausibility. As the Hon. Mark Falk, U.S.M.J, observed in High
5 Games, LLC v. Marks:
these claims are lathered in fact disputes that are inappropriate to conclusively
resolve in the context of a motion to amend. Amendment to the pleadings is a
fairly basic practice that does not rise to the level of dispositive motion practice.
And delving into the morass of fact questions inherent in these claims usurps
dispositive motion practice and amounts to making embedded factual findings and
dispositive decisions in the non-dispositive amendment context.
High 5 Games, LLC v. Marks, No. 13-7161, 2017 WL 349375, at *5 (D.N.J. Jan. 24, 2017).
Indeed, a motion for leave to amend under Rule 15 “does not require the parties to engage in the
equivalent of substantive motion practice upon the proposed new claim or defense; this does
require, however, that the newly asserted defense appear to be sufficiently well-grounded in fact
or law that it is not a frivolous pursuit.” Harrison Beverage Co. v. Dribeck Importers, Inc., 133
F.R.D. 463, 469 (D.N.J. 1990). Here, the Court finds the proposed amendment to be sufficiently
well-grounded as not to be frivolous, and it is not legally insufficient on its face. Under the
liberal standards of Rule 15, the Court is satisfied the amendment is not futile.
C. Timeliness
The Court has discretion to deny a motion for leave to amend based upon undue delay.
Notably, delay alone is insufficient grounds to deny an amendment. Cornell and Co., Inc. v.
Occupational Safety and Health Review Commission, 573 F.2d 820, 823 (3d Cir. 2001).
However, “at some point, the delay will become ‘undue,’ placing an unwarranted burden on the
22

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 23 of 27 PageID: 4487

court, or will become ‘prejudicial,’ placing an unfair burden on the opposing party.” Adams v.
Gould, 739 F.2d 858, 868 (3d Cir. 1984). In fact, prejudice “is the touchstone for the denial of an
amendment,” and a finding of unfair or substantial prejudice is sufficient ground for
denial. Cornell and Co., Inc., 573 F.2d at 823; Lorenz v. CSX Corporation, 1 F.3d 1406, 1414
(3d Cir. 1993). In evaluating the extent of any alleged prejudice, the Court looks to the hardship
on the non-moving party if the amendment were granted. Cureton v. NCAA, 252 F.3d 267, 273
(3d Cir. 2001).
Plaintiff contends that Sun’s motion is untimely because Defendants knew of the facts
underlying their inequitable conduct claims as early as February 2019 yet did not move to amend
until May 2022. Plaintiff claims that Defendants learned of Dr. Cholkar’s work in February
2019, when UMKC filed a lawsuit against Sun and other parties, alleging Dr. Cholkar was an
inventor to one of Sun’s patents. Plaintiff also notes that Sun had the belief that Dr. Cholkar was
an inventor to the Asserted Patents when Defendants asserted an implied license defense in their
Answer, which is dated June 2, 2021. When asked by Plaintiff about the factual basis for that
assertion, Defendants in their interrogatory responses dated May 11, 2022, explain the factual
basis for this defense as follows: “The alleged invention claimed in the Asserted Patents, on
which Dr. Cholkar is an unnamed co-inventor, is encompassed within the General Release
Agreement’s definition of Product and/or Related Product. Therefore, through the transfer and
assignment of rights from Dr. Cholkar to Sun recited in the General Release Agreement, Sun
acquired rights to the Asserted Patents and cannot infringe the Asserted Patents.” ECF No. 89-11
at 29. Thus, Plaintiff argues, Sun improperly delayed seeking to amend, and the motion should
be denied as untimely.

23

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 24 of 27 PageID: 4488

In response, Sun argues first that its motion comes within the time set by the Scheduling
Order. Sun also claims it required the documents it received from UMKC in late March “to
corroborate any claim of inventorship.” Sun states that inequitable conduct is a “serious
allegation and Sun does not make it lightly”, and it could not have made it without the
corroborating documents.
Sun disputes Plaintiff’s allegation that Sun’s implied license defense pled in its Answer
demonstrates that Sun knew the facts supporting its counterclaim at a much earlier time. Sun
claims (1) it had to plead all possible defenses in its answer to Aurinia’s complaint or risk
waiving its defenses; and (2) Sun pleading its implied license defense in its Answer is not akin to
Sun having discovered all of the facts and circumstances supporting its inequitable conduct
claims.
Sun contends that its knowledge that UMKC and Dr. Cholkar had previously alleged Dr.
Cholkar was a co-inventor of a different set of patents, is irrelevant. According to Sun, the
research work underlying those patents, which cover a different drug and different formulation,
had nothing to do with the research work that led to Aurinia’s presently Asserted Patents.
“[T]he question of undue delay requires that [the Court] focus on the movant’s reasons
for not amending sooner.” Cureton v. Nat'l Collegiate Athletic Ass'n, 252 F.3d 267, 273 (3d Cir.
2001). While it appears that Sun had formed a belief early in this litigation that Dr. Cholkar was
a co-inventor, Sun maintains that it was not possible to assert an inequitable conduct claim until
it received documents from UMKC in March 2022 allegedly corroborating its belief. Plaintiff
disputes this, arguing that 8 of the 9 documents produced by UMKC do not even mention Dr.
Cholkar’s name, and that the 9th document does not suggest that Dr. Cholkar is a co-inventor.

24

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 25 of 27 PageID: 4489

Sun responds that it is not uncommon for an investigator’s name to be left off of work product
and, in any event, Plaintiff’s argument raises a question of fact.
Indeed, what the documents establish as to Dr. Cholkar is a question of fact that is not for
the Court to determine on this motion for leave to amend. There does not appear to be a dispute
that the documents, at least in part, relate to Dr. Cholkar. As such, the Court credits Sun’s
assertion that it was not until it received the UMKC documents that it felt it was appropriate to
seek leave to amend to add the inequitable conduct claim. Moreover, while certainly not
dispositive of the issue of timeliness, the motion for leave to amend was filed within the time set
by the Scheduling Order. Taking all of these factors into consideration, the Court does not find
there was undue delay by Defendants in seeking leave to amend.
D. Prejudice
As to prejudice, Plaintiff claims allowing the proposed amendment enlarges the litigation,
imposing additional costs and likely delay as Defendants argue for more discovery. Plaintiff also
argues it allegedly forces Aurinia to choose between maintaining its trial date and perhaps
foregoing certain discovery or agreeing to push even further out its trial date while Defendants
continue to infringe Aurinia’s patents.
Sun, on the other hand, claims that Aurinia has not made any convincing showing of any
prejudice it would face if Sun’s proposed amended pleading is permitted because Sun’s
counterclaims do not add any new patents to this case. Additionally, Sun points out that Sun’s
allegations involve Mr. Michael Martin who was already listed in Aurinia’s Rule 26 disclosures
as early as July 2021. Mr. Martin was also already listed as one of Aurinia’s ESI discovery
custodians, and Sun has already noticed Mr. Martin for deposition.

25

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 26 of 27 PageID: 4490

As noted above, “prejudice to the non-moving party is the touchstone for the denial of an
amendment.” Lorenz v. CSX Corp., 1 F.3d 1406,1414 (3d Cir. 1993). In its evaluation of
prejudice to the non-moving party in the context of a motion to amend, courts consider whether
amendment would impair the non-moving party’s “ability to present its case.” Diebler v.
SanMedica Int'l, LLC, No. 19-20155, 2021 WL 5013617, at *4 (D.N.J. Oct. 28, 2021).
Importantly, “incidental prejudice to the opponent is not a sufficient basis for denial of an
amendment; such prejudice becomes “undue” when the opponent shows it would be “unfairly
disadvantaged or deprived of the opportunity to present facts or evidence which it would have
offered....” Harrison Beverage Co. v. Dribeck Importers, Inc., 133 F.R.D. 463, 468 (D.N.J.
1990). In determining whether undue prejudice will result if leave is granted, courts consider
whether the assertion of any new claim will: “(i) require the opponent to expend significant
additional resources to conduct discovery and prepare for trial; (ii) significantly delay the
resolution of the dispute; or (iii) prevent the plaintiff from bringing a timely action in another
jurisdiction.” Long v. Wilson, 393 F.3d 390, 400 (3d Cir. 2004).
The Court is not persuaded that permitting amendment at this point in the case would
significantly delay the resolution of this matter or deny Plaintiff the opportunity to present facts
or evidence to defend against Defendants’ claims. The amendment adds no new patents to the
case. Discovery is ongoing, and discovery involving Mr. Martin has already been noticed by
Defendants. The law requires leave to amend be liberally granted, and in its assessment of any
potential prejudice, the Court finds no basis to deny such leave.
III. Conclusion
This matter is before the Court a motion by Plaintiff for leave to amend its infringement
contentions (ECF No. 47); and a motion by Defendants for leave to amend their counterclaims

26

Case 3:20-cv-19805-GC-DEA Document 119 Filed 08/02/22 Page 27 of 27 PageID: 4491

(ECF No. 91). For the reasons above, Plaintiff’s motion is granted in part and denied in part, and
Sun’s motion is granted. An appropriate Order accompanies this Opinion.

s/ Douglas E. Arpert
DOUGLAS E. ARPERT
United States Magistrate Judge

Dated: August 2, 2022

27